

**AMENDMENTS TO THE CLAIMS:**

Please amend the claims as follows:

Claim 1. (Canceled)

2. (Currently Amended) An isolated ~~isolated~~ antigenic polypeptide[[s]] ~~according to claim 1~~ obtainable by a process comprising the steps of :

a-selecting on the basis of sequence analysis ~~these of the~~ polypeptides which are either located in the outer membrane or secreted by ~~[[the]]a~~ bacteria,

b-identifying the genes coding for said polypeptides which are conserved in B2/D E. coli clinical isolates,

c-~~preparing~~ purifying the polypeptides selected ~~[[identified]]~~ in step a, which are found in step b to be conserved in B2/D E. coli isolates,

d-testing the polypeptides for immunogenicity using an animal[[s]] model[[s]] and isolating polypeptides which are antigenic.

Claims 3-8. (Canceled)

9. (Currently Amended) An isolated polypeptide ~~which is an~~ selected in the group consisting of SEQ ID NOs:1 to 66 and 133-145, or an antigenic fragment of SEQ ID NO: ~~134s:1-66 and 133-145~~, provided that said polypeptide is not SEQ ID NO:8.

10. (Currently Amended) A vaccine composition specific to *E. coli* extra-intestinal infections, comprising an effective amount of at least one polypeptide ~~with a sequence selected in the group consisting of~~ having the sequence set forth in SEQ ID NO:134 or a sequence which is an antigenic fragment of SEQ ID NO:134, provided that said antigenic fragment is not a peptide consisting of a sequence set forth in SEQ ID

NO:1 to SEQ ID NOs:66, or 133-145, except SEQ ID NO:8, said composition further comprising [[with]] a pharmaceutically acceptable carrier.

11. (Currently Amended) The vaccine composition of claim 10 ~~[[for]]~~ in a form administerable for treatment of a urinary system infection, pyelonephritis, sepsis, bacteremia, or neonatal meningitis.

12. (Previously Presented) The vaccine composition of claim 10, further comprising at least one component of *S. aureus* or a group *B Streptococcus*.

Claims 13-14. (Canceled)

15. (Withdrawn – Currently Amended) A method for detecting the presence or absence of undesirable extra-intestinal *E. coli*, and/or for the diagnosis of an extra-intestinal *E. coli* infection, comprising the use of the at least one polypeptide having a sequence set forth in SEQ ID NO:134 or a polypeptide defined in claim 9[[1]] or a polynucleotide encoding the said polypeptide, or an antibody reactive to said polypeptide, said polypeptide being optionally in combination with at least one polypeptide having a sequence selected from the group consisting of SEQ ID NOs:1-66 and 133-145.

16. (Currently Amended) Pharmaceutical composition for alleviating and/or preventing and/or treating an undesirable growth of *E. coli* comprising an effective amount of at least one polypeptide having a sequence set forth in SEQ ID NO:134 or a polypeptide according to claim 9, in combination with a pharmaceutically acceptable carrier.

Claim 17. (Canceled)

18. (Currently Amended) A composition comprising a polypeptide having a sequence set forth in SEQ ID NO:134 or a polypeptide of claim 9, provided that said polypeptide does not consist of a sequence set forth in SEQ ID NO:8~~sequence selected in the group consisting of SEQ ID NOs:1-66 and 133-145,~~ with a pharmaceutically acceptable carrier.

19. (Currently Amended) The composition of claim 18 wherein said polypeptide has a sequence set forth in~~sequence is~~ SEQ ID NO:134.

20. (Withdrawn – Currently Amended) A method of making a composition of claim 18 comprising combining said polypeptide~~sequence~~ and said carrier.

21. (Withdrawn – Currently Amended) The method of claim 20 wherein said polypeptide has the sequence set forth in~~in~~ SEQ ID NO:134.

22. (new) A human vaccine specific to B2/D *E. coli* extra- intestinal infections, comprising an effective amount of a polypeptide having the sequence set forth in SEQ ID NO:134, and a pharmaceutically acceptable carrier.

23. (new) The vaccine composition of claim 22 in a form administerable for treatment of a urinary system infection, pyelonephritis, sepsis, bacteremia, or neonatal meningitis.

24. (new) The vaccine composition of claim 22, further comprising at least one component of *S. aureus* or a group *B Streptococcus*.

25. (new) A pharmaceutical composition for treating an undesirable growth of B2/D *E. coli* comprising an effective amount of a polypeptide having a sequence set forth in SEQ ID NO:134, in combination with a pharmaceutically acceptable carrier.

26. (new) A human vaccine specific to B2/D *E. coli* extra- intestinal infections, comprising an effective amount of a polypeptide having the sequence of an antigenic fragment of the sequence set forth in SEQ ID NO:134, and a pharmaceutically acceptable carrier.

27. (new) The vaccine composition of claim 26 in a form administerable for treatment of a urinary system infection, pyelonephritis, sepsis, bacteremia, or neonatal meningitis.

28. (new) The vaccine composition of claim 26, further comprising at least one component of *S. aureus* or a group *B Streptococcus*.

29. (new) A pharmaceutical composition for treating an undesirable growth of B2/D *E. coli* comprising an effective amount of a polypeptide having the sequence of an antigenic fragment of the sequence set forth in SEQ ID NO:134, in combination with a pharmaceutically acceptable carrier.